Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer
NCT03053167Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, raltitrexed in colorectal cancer (CRC), sponsored by China Medical University. Status: unknown.
02
Drugs
irinotecanraltitrexed
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03053167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053167.